HRP20211026T1 - Metoda za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji - Google Patents
Metoda za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji Download PDFInfo
- Publication number
- HRP20211026T1 HRP20211026T1 HRP20211026TT HRP20211026T HRP20211026T1 HR P20211026 T1 HRP20211026 T1 HR P20211026T1 HR P20211026T T HRP20211026T T HR P20211026TT HR P20211026 T HRP20211026 T HR P20211026T HR P20211026 T1 HRP20211026 T1 HR P20211026T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- aqueous solution
- conductivity
- protein
- igg1
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- 102000004169 proteins and genes Human genes 0.000 title claims 14
- 108090000623 proteins and genes Proteins 0.000 title claims 14
- 238000001042 affinity chromatography Methods 0.000 title claims 2
- 239000007864 aqueous solution Substances 0.000 claims 21
- 238000004587 chromatography analysis Methods 0.000 claims 6
- 239000000463 material Substances 0.000 claims 6
- 238000005406 washing Methods 0.000 claims 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 3
- 102000003780 Clusterin Human genes 0.000 claims 3
- 108090000197 Clusterin Proteins 0.000 claims 3
- 102000015439 Phospholipases Human genes 0.000 claims 3
- 108010064785 Phospholipases Proteins 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 108010048049 Factor IXa Proteins 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 102000008212 P-Selectin Human genes 0.000 claims 2
- 108010035766 P-Selectin Proteins 0.000 claims 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 208000037798 influenza B Diseases 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 2
- 235000011009 potassium phosphates Nutrition 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Claims (20)
1. Uporaba vodene otopine niske vodljivosti u koraku ispiranja proteina A za kromatografiju za smanjenje sadržaja proteina stanice domaćina, pri čemu se protein A za kromatografiju koristi za pročišćavanje humanog izotipskog protutijela IgG4 ili IgG1, pri čemu vodena otopina niske vodljivosti ima vrijednost vodljivosti od oko 0,5 mS/cm ili manje, pri čemu je protein stanice domaćina fosfolipazi B-sličan 2 (PLBL2) ili klusterin.
2. Uporaba prema patentnom zahtjevu 1, naznačena time, da vodena otopina niske vodljivosti sadrži oko 0,1 mM do oko 8 mM Tris.
3. Uporaba prema patentnom zahtjevu 1, naznačena time, da vodena otopina niske vodljivosti sadrži oko 0,05 mM do oko 2 mM kalijev fosfata.
4. Uporaba prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time, da vodena otopina niske vodljivosti ima pH vrijednost oko 7 ili veću.
5. Uporaba prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da koraku ispiranja vodenom otopinom niske vodljivosti prethodi ili slijedi korak ispiranja vodenom otopinom visoke vodljivosti.
6. Uporaba prema patentnom zahtjevu 5, naznačena time, da vodena otopina visoke vodljivosti ima vrijednost vodljivosti od oko 20 mS/cm ili veću.
7. Uporaba prema bilo kojem od patentnih zahtjeva 5 do 6, naznačena time, da vodena otopina visoke vodljivosti sadrži histidin.
8. Uporaba prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time, da je humano izotipsko protutijelo IgG4 protutijelo na P-selektin ili protutijelo na faktor IXa i faktor X ili protutijelo na IL-13 ili protutijelo na beta amiloid.
9. Uporaba prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time, da je humano izotipsko protutijelo IgG1 protutijelo na influencu B ili protutijelo na VEGF-A ili protutijelo na CD22 ili bispecifično protutijelo na HER3 i EGFR ili protutijelo na beta amiloid ili protutijelo na Her2 ili bispecifično protutijelo na Ang2 i VEGF-A ili bispecifično protutijelo na karcinoembrionalni antigen (CEA) i CD3.
10. Metoda za dobivanje humanog izotipskog protutijela IgG4 ili IgG1, koja obuhvaća korake za
a) kultiviranje stanice koja sadrži nukleinsku kiselinu koja kodira humano izotipsko protutijelo IgG4 ili IgG1
b) vraćanje humanog izotipskog protutijela IgG4 ili IgG1 iz stanice ili kultivacijskog medija
c) kontaktiranje humanog izotipskog protutijela IgG4 ili IgG1 s materijalom proteina A za kromatografiju
d) ispiranje materijala proteina A za kromatografiju vodenom otopinom niske vodljivosti, pri čemu vodena otopina niske vodljivosti ima vrijednost vodljivosti od oko 0,5 mS/cm ili manje, pri čemu je smanjena količina proteina stanice domaćina i pri čemu je spomenuti protein stanice domaćina fosfolipazi B-sličan 2 (PLBL2) ili klusterin
e) obnavljanje humanog izotipskog protutijela IgG4 ili IgG1 iz materijala proteina A za kromatografiju
i na taj način se proizvodi humano izotipsko protutijelo IgG4 ili IgG1.
11. Metoda za pročišćavanje humanog izotipskog protutijela IgG4 ili IgG1 iz uzorka, koja sadrži korake za
a) dostavljanje uzorka koji sadrži humano izotipsko protutijelo IgG4 ili IgG1
b) pročišćavanje humanog izotipskog protutijela IgG4 ili IgG1 kromatografskim postupkom/korakom za protein A, koji uključuje ispiranje materijala proteina A za kromatografiju vodenom otopinom niske vodljivosti, pri čemu vodena otopina niske vodljivosti ima vodljivost od oko 0,5 mS/cm ili manje, pri čemu je količina proteina stanice domaćina smanjena i pri čemu je spomenuti protein stanice domaćina fosfolipazi B-sličan 2 (PLBL2) ili klusterin.
12. Metoda prema bilo kojem od patentnih zahtjeva 10 do 11, naznačena time, da vodena otopina niske vodljivosti sadrži oko 0,1 mM do oko 8 mM Tris.
13. Metoda prema bilo kojem od patentnih zahtjeva 10 do 12, naznačena time, da vodena otopina niske vodljivosti sadrži oko 0,05 mM do oko 2 mM kalijev fosfata.
14. Metoda prema bilo kojem od patentnih zahtjeva 10 do 13, naznačena time, da vodena otopina niske vodljivosti ima pH vrijednost oko 7 ili veću.
15. Metoda prema bilo kojem od patentnih zahtjeva 10 do 14, naznačena time, da metoda dodatno uključuje ispiranje materijala za afinitetnu kromatografiju vodenom otopinom visoke vodljivosti i/ili vodenom otopinom srednje vodljivosti prije ili nakon pranja materijala proteina A za kromatografiju vodenom otopinom slabe vodljivosti.
16. Metoda prema patentnom zahtjevu 15, naznačena time, da vodena otopina visoke vodljivosti ima vrijednost vodljivosti od oko 20 mS/cm ili veću.
17. Metoda prema patentnom zahtjevu 15, naznačena time, da vodena otopina srednje vodljivosti ima vrijednost vodljivosti od više od 0,5 mS/cm do manje od 20 mS/cm.
18. Metoda prema bilo kojem od patentnih zahtjeva 15 do 17, naznačena time, da vodena otopina visoke ili srednje vodljivosti sadrži histidin.
19. Metoda prema bilo kojem od patentnih zahtjeva 10 do 18, naznačena time, da je humano izotipsko protutijelo IgG4 protutijelo na P-selektin ili protutijelo na faktor IXa i faktor X ili protutijelo na IL-13 ili protutijelo na beta amiloid.
20. Metoda prema bilo kojem od patentnih zahtjeva 10 do 18, naznačena time, da je humano izotipsko protutijelo IgG1 protutijelo na influencu B ili protutijelo na VEGF-A ili protutijelo na CD22 ili bispecifično protutijelo na HER3 i EGFR ili protutijelo na beta amiloid ili protutijelo na Her2 ili bispecifično protutijelo na Ang2 i VEGF-A ili bispecifično protutijelo na karcinoembrionalni antigen (CEA) i CD3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208523P | 2015-08-21 | 2015-08-21 | |
| PCT/EP2016/069604 WO2017032686A1 (en) | 2015-08-21 | 2016-08-18 | Method for the reduction of host cell proteins in affinity chromatography |
| EP16757608.1A EP3337812B1 (en) | 2015-08-21 | 2016-08-18 | Method for the reduction of host cell proteins in affinity chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211026T1 true HRP20211026T1 (hr) | 2021-10-01 |
Family
ID=56802471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211026TT HRP20211026T1 (hr) | 2015-08-21 | 2021-06-29 | Metoda za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180186832A1 (hr) |
| EP (1) | EP3337812B1 (hr) |
| JP (3) | JP6968055B2 (hr) |
| KR (1) | KR20180034500A (hr) |
| CN (2) | CN107849087B (hr) |
| AU (1) | AU2016312909B2 (hr) |
| BR (1) | BR112018001511A2 (hr) |
| CA (1) | CA2992420A1 (hr) |
| ES (1) | ES2877532T3 (hr) |
| HK (1) | HK1251584A1 (hr) |
| HR (1) | HRP20211026T1 (hr) |
| IL (1) | IL257146A (hr) |
| MX (1) | MX2018001536A (hr) |
| PL (1) | PL3337812T3 (hr) |
| SI (1) | SI3337812T1 (hr) |
| WO (1) | WO2017032686A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2925033T3 (es) | 2014-09-10 | 2022-10-13 | Procter & Gamble | Banda no tejida |
| WO2017032610A1 (en) * | 2015-08-21 | 2017-03-02 | F. Hoffmann-La Roche Ag | Affinity chromatography purification with low conductivity wash buffer |
| WO2017032686A1 (en) | 2015-08-21 | 2017-03-02 | F. Hoffmann-La Roche Ag | Method for the reduction of host cell proteins in affinity chromatography |
| SI3337817T1 (sl) | 2015-08-21 | 2021-12-31 | F. Hoffmann - La Roche Ag | Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji |
| KR20200141473A (ko) * | 2018-05-04 | 2020-12-18 | 시그마-알드리치 컴퍼니., 엘엘씨 | 숙주 세포 단백질의 감소된 수준을 갖는 재조합 단백질 생산 |
| US20220267369A1 (en) * | 2018-07-25 | 2022-08-25 | Merck Sharp & Dohme Corp. | Methods of separating host cell lipases from a production protein in chromatographic processes |
| EP4034546A4 (en) * | 2019-09-23 | 2024-01-31 | Merck Sharp & Dohme LLC | METHODS AND COMPOSITIONS COMPRISING AN ANTI-CTLA4 MONOCLONAL ANTIBODY COMPRISING REDUCED AND INCREASED STABILITY HOST CELL PROTEINS OF POLYSORBATE-80 |
| WO2023284073A1 (zh) * | 2021-07-13 | 2023-01-19 | 江苏荃信生物医药股份有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂 |
| WO2023137143A1 (en) * | 2022-01-14 | 2023-07-20 | Shattuck Labs, Inc. | Methods of contaminant removal from protein isolates |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003262087B2 (en) | 2002-09-11 | 2010-11-11 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| WO2007068429A1 (en) * | 2005-12-12 | 2007-06-21 | F. Hoffmann-La Roche Ag | Antibodies against amyloid beta 4 with glycosylated in the variable region |
| US8263750B2 (en) | 2006-03-16 | 2012-09-11 | Amgen Inc. | Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step |
| WO2011038894A1 (en) * | 2009-10-01 | 2011-04-07 | F. Hoffmann-La Roche Ag | Protein a chromatography |
| WO2011073389A1 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | Wash solution and method for affinity chromatography |
| EP2583973B1 (en) * | 2010-06-21 | 2018-03-21 | Kyowa Hakko Kirin Co., Ltd. | Method for purifying protein using amino acid |
| CA2910065C (en) | 2013-05-15 | 2023-09-19 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| AR096713A1 (es) * | 2013-06-25 | 2016-01-27 | Cadila Healthcare Ltd | Proceso de purificación para anticuerpos monoclonales |
| US10144774B2 (en) * | 2013-07-01 | 2018-12-04 | Csl Behring Ag | Method for purifying IgG |
| CN105473612A (zh) * | 2013-08-19 | 2016-04-06 | 豪夫迈·罗氏有限公司 | 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物 |
| EP3683232A1 (en) * | 2013-09-13 | 2020-07-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| CN103497248B (zh) * | 2013-09-22 | 2016-08-10 | 中国抗体制药有限公司 | 一种从细胞培养上清中分离纯化抗体的方法 |
| SI3337817T1 (sl) | 2015-08-21 | 2021-12-31 | F. Hoffmann - La Roche Ag | Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji |
| WO2017032686A1 (en) | 2015-08-21 | 2017-03-02 | F. Hoffmann-La Roche Ag | Method for the reduction of host cell proteins in affinity chromatography |
-
2016
- 2016-08-18 WO PCT/EP2016/069604 patent/WO2017032686A1/en active Application Filing
- 2016-08-18 PL PL16757608T patent/PL3337812T3/pl unknown
- 2016-08-18 CN CN201680042079.1A patent/CN107849087B/zh active Active
- 2016-08-18 EP EP16757608.1A patent/EP3337812B1/en active Active
- 2016-08-18 CN CN202211094785.4A patent/CN116063375A/zh active Pending
- 2016-08-18 ES ES16757608T patent/ES2877532T3/es active Active
- 2016-08-18 BR BR112018001511A patent/BR112018001511A2/pt active Search and Examination
- 2016-08-18 JP JP2018509846A patent/JP6968055B2/ja active Active
- 2016-08-18 CA CA2992420A patent/CA2992420A1/en active Pending
- 2016-08-18 AU AU2016312909A patent/AU2016312909B2/en active Active
- 2016-08-18 KR KR1020187004868A patent/KR20180034500A/ko active IP Right Grant
- 2016-08-18 SI SI201631245T patent/SI3337812T1/sl unknown
- 2016-08-18 MX MX2018001536A patent/MX2018001536A/es unknown
-
2018
- 2018-01-25 IL IL257146A patent/IL257146A/en unknown
- 2018-02-20 US US15/900,461 patent/US20180186832A1/en not_active Abandoned
- 2018-08-23 HK HK18110896.4A patent/HK1251584A1/zh unknown
-
2021
- 2021-05-24 US US17/328,408 patent/US20220169675A1/en active Pending
- 2021-06-29 HR HRP20211026TT patent/HRP20211026T1/hr unknown
- 2021-07-30 JP JP2021124951A patent/JP7258964B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061111A patent/JP2023076617A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116063375A (zh) | 2023-05-05 |
| JP2021176900A (ja) | 2021-11-11 |
| BR112018001511A2 (pt) | 2018-09-18 |
| EP3337812A1 (en) | 2018-06-27 |
| MX2018001536A (es) | 2018-04-24 |
| ES2877532T3 (es) | 2021-11-17 |
| KR20180034500A (ko) | 2018-04-04 |
| HK1251584A1 (zh) | 2019-02-01 |
| US20180186832A1 (en) | 2018-07-05 |
| IL257146A (en) | 2018-03-29 |
| JP6968055B2 (ja) | 2021-11-17 |
| CN107849087A (zh) | 2018-03-27 |
| CN107849087B (zh) | 2022-09-06 |
| AU2016312909B2 (en) | 2022-12-08 |
| EP3337812B1 (en) | 2021-04-28 |
| PL3337812T3 (pl) | 2021-10-11 |
| JP7258964B2 (ja) | 2023-04-17 |
| CA2992420A1 (en) | 2017-03-02 |
| JP2018531895A (ja) | 2018-11-01 |
| SI3337812T1 (sl) | 2021-08-31 |
| US20220169675A1 (en) | 2022-06-02 |
| AU2016312909A1 (en) | 2018-02-22 |
| WO2017032686A1 (en) | 2017-03-02 |
| JP2023076617A (ja) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211026T1 (hr) | Metoda za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji | |
| HRP20191865T1 (hr) | Novi heterodimerni proteini | |
| JP2016530533A5 (hr) | ||
| HRP20200189T1 (hr) | Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije | |
| HRP20210096T1 (hr) | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| JP7137663B2 (ja) | 多量体タンパク質の純度の決定 | |
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| HRP20171095T4 (hr) | Postupci pročišćavanja polipeptida | |
| HRP20150262T1 (hr) | Miševi sa adam6 | |
| EA201892522A1 (ru) | Днк-моноклональные антитела, нацеленные на молекулы контрольных точек | |
| PH12018501282A1 (en) | Anti-c5 antibodies and methods of use | |
| NZ627668A (en) | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography | |
| RU2014111820A (ru) | Способы элиминации вируса | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| CL2008003784A1 (es) | Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo | |
| MX2020000288A (es) | Cromatografia. | |
| HRP20211737T1 (hr) | Postupak za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji | |
| HRP20220884T1 (hr) | Proteini specifični za baff i b7rp1 i njihova uporaba | |
| ZA202104048B (en) | Anti-il-17a antibody and use thereof | |
| MX2023007583A (es) | Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen. | |
| EA202092769A1 (ru) | Антитела против cd63, их конъюгаты и применения | |
| AR109237A1 (es) | Anticuerpos contra ip-10 y sus usos | |
| AR105762A1 (es) | Anticuerpos anti-ccl-1 y métodos de uso |